Literature DB >> 2210054

Structure of cat islet amyloid polypeptide and identification of amino acid residues of potential significance for islet amyloid formation.

C Betsholtz1, L Christmanson, U Engström, F Rorsman, K Jordan, T D O'Brien, M Murtaugh, K H Johnson, P Westermark.   

Abstract

Cats and humans, unlike most rodent species, develop amyloid in the islets of Langerhans in conjunction with non-insulin-dependent diabetes mellitus. The amyloid consists of a 37-amino acid polypeptide referred to as islet amyloid polypeptide (IAPP). The primary structures of IAPP from human and three rodent species have previously been determined. Sequence divergence was seen in the region corresponding to amino acid residues 20-29, which in human IAPP has been suggested to confer the amyloidogenic properties to the molecule. Using polymerase chain-reaction methodology, we determined the primary sequence of cat IAPP. Amino acid region 20-29 shows specific similarities and differences compared with human and rodent IAPP, respectively. A synthetic cat IAPP20-29 decapeptide formed amyloid fibrils spontaneously in vitro. Comparison between the structure and amyloid fibril-forming activity of various synthetic peptides suggests that the amino acid residues at positions 25-26 in mature IAPP are important for the amyloidogenic properties of the molecule.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210054     DOI: 10.2337/diacare.39.1.118

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  18 in total

1.  Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: implications for the study of amyloid formation.

Authors:  Melanie R Nilsson; Miles Driscoll; Daniel P Raleigh
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

Review 2.  Islet amyloid polypeptide--a novel controversy in diabetes research.

Authors:  P Westermark; K H Johnson; T D O'Brien; C Betsholtz
Journal:  Diabetologia       Date:  1992-04       Impact factor: 10.122

3.  Islet amyloid polypeptide in insulinoma and in the islets of the pancreas of non-diabetic and diabetic subjects.

Authors:  H Toshimori; R Narita; M Nakazato; J Asai; T Mitsukawa; K Kangawa; H Matsuo; K Takahashi; S Matsukura
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

4.  Circadian anorectic effects of peripherally administered amylin in rats.

Authors:  T A Lutz; E Del Prete; M M Szabady; E Scharrer
Journal:  Z Ernahrungswiss       Date:  1995-09

5.  Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation.

Authors:  P Westermark; U Engström; K H Johnson; G T Westermark; C Betsholtz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

6.  Involvement of ATP-sensitive potassium (K(ATP)) channels in the loss of beta-cell function induced by human islet amyloid polypeptide.

Authors:  Maud Soty; Montse Visa; Sergi Soriano; María del Carmen Carmona; Ángel Nadal; Anna Novials
Journal:  J Biol Chem       Date:  2011-10-07       Impact factor: 5.157

Review 7.  Neuroendocrine hormone amylin in diabetes.

Authors:  Xiao-Xi Zhang; Yan-Hong Pan; Yan-Mei Huang; Hai-Lu Zhao
Journal:  World J Diabetes       Date:  2016-05-10

Review 8.  Amylin-mediated control of glycemia, energy balance, and cognition.

Authors:  Elizabeth G Mietlicki-Baase
Journal:  Physiol Behav       Date:  2016-02-27

9.  Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide.

Authors:  C B Verchere; D A D'Alessio; R D Palmiter; G C Weir; S Bonner-Weir; D G Baskin; S E Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

10.  Islet amyloid polypeptide in the rabbit and European hare: studies on its relationship to amyloidogenesis.

Authors:  L Christmanson; C Betsholtz; A Leckström; U Engström; C Cortie; K H Johnson; T E Adrian; P Westermark
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.